The progress quietly made by Sino-American biotech company BeiGene (Nasdaq: BGNE) with its oral Bruton tyrosine kinase inhibitor (BTKi) Brukinsa (zanubrutinib) since 2019 has been nothing short of remarkable.
Impressive late-stage data readouts and regulatory approvals have come thick and fast in the indications of chronic lymphocytic leukemia or small lymphocytic leukemia, mantle cell lymphoma and relapsed or refractory marginal zone lymphoma who have received at least one prior therapy, and Waldenström’s macroglobulinemia.
Brukinsa has also outperformed AbbVie’s (NYSE: ABBV) Imbruvica (ibrutinib), which has been the standard of care in chronic lymphocytic leukemia, for almost a decade.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze